---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071390"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:57:49.417301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q1 net revenue rises to $293K; net loss narrows to $3.8M

## Summary
- Net product revenue ~$293K, a four-fold increase from Q4 2024's $68K.
- Net loss of $3.8M ($0.44/share) vs $12.7M ($4.73/share) a year ago.
- NEUTRALIZE-AKI trial 50% enrolled; interim analysis by DSMB expected Q3 2025.
- Two new Breakthrough Device Designations for SCD therapy in cardiac surgery (adult & ped).
- Cash $5.3M as of March 31, 2025 vs $1.8M Dec 31, 2024; $6M offering closed Jan 2025.

## SEC filing metadata
- accession: 0000950170-25-071390
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/0000950170-25-071390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000095017025071390/icu-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071390
- JSON: https://secwatch.observer/filing/0000950170-25-071390.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.